BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Falcão EM, Trope BM, Godinho MM, Carneiro LH, de Araujo-Neto JM, Nogueira CA, Ramos-E-Silva M. Cutaneous Eruption due to Telaprevir. Case Rep Dermatol 2015;7:253-62. [PMID: 26500538 DOI: 10.1159/000439264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Scavone C, Sportiello L, Rafaniello C, Mascolo A, Sessa M, Rossi F, Capuano A. New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). Expert Opinion on Drug Safety 2016;15:85-100. [DOI: 10.1080/14740338.2016.1221396] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
2 Othumpangat S, Ray SD, Noti JD. Antiviral Drugs. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Elsevier; 2016. pp. 261-81. [DOI: 10.1016/bs.seda.2016.08.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Wang Y, Liu P. A case of erythema multiforme drug eruption associated with erythrodermic psoriasis induced by sofosbuvir and daclatasvir. J Clin Pharm Ther 2017;42:108-10. [PMID: 27757979 DOI: 10.1111/jcpt.12467] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Yang Y, Dang SS. Safety of direct antiviral agents for treatment of hepatitis C virus infection. Shijie Huaren Xiaohua Zazhi 2017; 25(8): 659-669 [DOI: 10.11569/wcjd.v25.i8.659] [Reference Citation Analysis]